Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia

被引:2
|
作者
Alkhatabi, Heba [1 ,2 ]
Bin Saddeq, Haneen Abdulfattah [3 ]
Alyamani, Luay [4 ]
Shinawi, Thoraia [1 ]
Yasin, Elrashed B. [5 ]
Alserihi, Raed [1 ,6 ]
Felimban, Raed [1 ,6 ]
Tayeb, Hossam H. [1 ,6 ]
Mimani, Rawan [2 ]
Alalla, Zainab [2 ]
Abu-Elmagd, Muhammad [2 ]
Abuzenadah, Adel [1 ,7 ]
机构
[1] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah 80200, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Excellence Genom Med Res CEGMR, Jeddah 80200, Saudi Arabia
[3] King Abdullah Med City, Mecca 24246, Saudi Arabia
[4] King Saud Bin Abdelaziz Univ Hlth Sci, Coll Med, Basic Med Sci Dept, Jeddah 80200, Saudi Arabia
[5] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Rabigh 25732, Saudi Arabia
[6] King Abdulaziz Univ, Ctr Innovat Personalized Med CIPM, Jeddah 80200, Saudi Arabia
[7] King Abdulaziz Univ, King Fahad Med Res Ctr KFMRC, Jeddah 80200, Saudi Arabia
关键词
IDH1; IDH2; AML; ALL; ACUTE MYELOID-LEUKEMIA; IDH2; MUTATIONS; FREQUENCY;
D O I
10.3390/genes12121963
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas
    Yu Lei
    Qi Song-tao
    Li Zhi-yong
    CHINESE MEDICAL JOURNAL, 2010, 123 (24) : 3697 - 3705
  • [32] Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia
    Kovy, Petra
    Orfi, Zoltan
    Bors, Andras
    Kozma, Andras
    Gopcsa, Laszlo
    Dolgos, Janos
    Lovas, Nora
    Harasztdombi, Jozsef
    Lakatos, Viktor
    Kiraly, Agnes
    Mikala, Gabor
    Valyi-Nagy, Istvan
    Remenyi, Peter
    Andrikovics, Hajnalka
    PLOS ONE, 2021, 16 (06):
  • [33] Analysis of KRAS and NRAS in Patients with Leukemia in Saudi Arabia
    Altayar, Malik A.
    Al-Amer, Osama M.
    BIOSCIENCE RESEARCH, 2022, 19 (03): : 1504 - 1511
  • [34] Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials
    Aiman, Wajeeha
    Ali, Muhammad Ashar
    Basit, Muhammad Abdul
    Omar, Zainab
    Suleman, Muhammad
    Hassan, Muhammad
    Jamil, Taimoor
    Anwar, Muhammad Saad
    Shafique, Zubair
    Dhanesar, Gurneel
    Faisal, Muhammad Salman
    Akerman, Michael J.
    Maroules, Michael
    Anwer, Faiz
    LEUKEMIA RESEARCH, 2023, 129
  • [35] Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia
    Lu, Jingtao
    Chen, Meiyu
    Hua, Haiying
    Qin, Wei
    Zhang, Ri
    Lu, Xuzhang
    Chao, Hongying
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (06) : 1483 - 1490
  • [36] Acute myeloid leukemia treatment outcomes with isocitrate dehydrogenase mutations: A systematic review and meta-analysis
    Qin, Han
    Xu, Rui
    Yang, Yingchao
    MEDICINE, 2024, 103 (49) : e40565
  • [37] Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
    Testa, Ugo
    Castelli, Germana
    Pelosi, Elvira
    CANCERS, 2020, 12 (09) : 1 - 44
  • [38] The diagnostic Value of Isocitrate Dehydrogenase Mutations in Patients with Chondrosarcoma
    Juratli, Tareq A.
    OSTEOLOGIE, 2022, 31 (01) : 73 - 74
  • [39] Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations
    Linos, Konstantinos
    Tafe, Laura J.
    HISTOPATHOLOGY, 2018, 73 (06) : 963 - 968
  • [40] Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms
    Babakoohi, Shahab
    Lapidus, Rena G.
    Faramand, Rawan
    Sausville, Edward A.
    Emadi, Ashkan
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2017, 25 (05) : 334 - 337